That such a focus may have therapeutic implications, we note that the SERT/NET blocker venlafaxine has shown efficacy in clinical trials for ADHD treatment comparable to psychostimulant medications, with a better side effect profile [55, 56]. This evidence concerns the gene SLC6A4 and attention deficit-hyperactivity disorder.